<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03415386</url>
  </required_header>
  <id_info>
    <org_study_id>OATH-AMI</org_study_id>
    <nct_id>NCT03415386</nct_id>
  </id_info>
  <brief_title>Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus</brief_title>
  <acronym>OATH-AMI</acronym>
  <official_title>A Multi-center Study on the Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center study will be done to explore the optimal regimen of antithrombotic therapy
      for acute myocardial infarction with left ventricular mural thrombus. The investigators will
      evaluate the different combinations of antiplatelet drugs and anticoagulants for at least one
      month, such as aspirin 100mg qd+clopidogrel 75mg qd+warfarin (INR1.8-2.5), aspirin 100mg
      qd+clopidogrel 75mg qd+dabigatran 110mg bid, aspirin 100mg qd+ticagrelor 60mg bid+warfarin
      (INR1.8-2.5), and aspirin 100mg qd+ticagrelor 60mg bid+dabigatran 110mg bid. Transthoracic
      two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups
      to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic
      therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel 75mg
      qd/ticagrelor 60mg bid. Then the investigators will complete the 12-month follow-up to
      evaluate the efficacy and safety of the optimal antithrombotic therapy regimen for acute
      myocardial infarction with left ventricular mural thrombus.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular mural thrombus</measure>
    <time_frame>1-month</time_frame>
    <description>Whether the left ventricular mural thrombus dissolves</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular mural thrombus-remain or recurrent</measure>
    <time_frame>3-month</time_frame>
    <description>Whether the mural thrombus remain or recurrent in left ventricular</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular mural thrombus-still remain or recurrent</measure>
    <time_frame>6-month</time_frame>
    <description>Whether the mural thrombus still remain or recurrent in left ventricular</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke or other systemic circulation embolism</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent restenosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major cardio-cerebral vascular events</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of any events from outcome 2 to 6</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Major bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>Bleeding Academic Research Consortium (BARC) bleedings ≥ 2</description>
  </other_outcome>
  <other_outcome>
    <measure>Minor bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>BARC bleedings &lt; 2</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Left Ventricular Thrombus</condition>
  <arm_group>
    <arm_group_label>aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin100mg qd+ticagrelor60mg bid+warfarin(INR1.8-2.5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination of antiplatelet drugs and anticoagulants for at least one month</intervention_name>
    <description>Combination of antiplatelet drugs and anticoagulants for at least one month, such as aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.5), aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid, aspirin100mg qd+ticagrelor60mg bid+warfarin (INR1.8-2.5), and aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid. Transthoracic two-dimensional echocardiography will be done at the 1-month, 3-month and 6-month follow-ups to evaluate the left ventricular mural thrombus and determinate whether the antithrombotic therapy regimen could be regulated to double antiplatelet or anticoagulant+clopidogrel75mg qd/ticagrelor60mg bid.</description>
    <arm_group_label>aspirin100mg qd+clopidogrel75mg qd+warfarin (INR1.8-2.5)</arm_group_label>
    <arm_group_label>aspirin100mg qd+clopidogrel75mg qd+dabigatran110mg bid</arm_group_label>
    <arm_group_label>aspirin100mg qd+ticagrelor60mg bid+warfarin(INR1.8-2.5)</arm_group_label>
    <arm_group_label>aspirin100mg qd+ticagrelor60mg bid+dabigatran110mg bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute myocardial infarction with left ventricular mural thrombus

        Exclusion Criteria:

          -  BARC bleedings ≥ 2

          -  atrial fibrillation

          -  acute stroke or other systemic circulation embolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liansheng Wang, Doctor</last_name>
    <phone>86 25 68303125</phone>
    <email>drlswang@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haoyu Meng, Doctor</last_name>
    <phone>86 25 68303126</phone>
    <email>haoyu_meng@163.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S; ESC Scientific Document Group . 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29.</citation>
    <PMID>26320110</PMID>
  </reference>
  <reference>
    <citation>Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P; ESC Scientific Document Group . 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393.</citation>
    <PMID>28886621</PMID>
  </reference>
  <reference>
    <citation>Reeder GS, Lengyel M, Tajik AJ, Seward JB, Smith HC, Danielson GK. Mural thrombus in left ventricular aneurysm: incidence, role of angiography, and relation between anticoagulation and embolization. Mayo Clin Proc. 1981 Feb;56(2):77-81.</citation>
    <PMID>7464234</PMID>
  </reference>
  <reference>
    <citation>Turpie AG, Robinson JG, Doyle DJ, Mulji AS, Mishkel GJ, Sealey BJ, Cairns JA, Skingley L, Hirsh J, Gent M. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med. 1989 Feb 9;320(6):352-7.</citation>
    <PMID>2643772</PMID>
  </reference>
  <reference>
    <citation>Keeley EC, Hillis LD. Left ventricular mural thrombus after acute myocardial infarction. Clin Cardiol. 1996 Feb;19(2):83-6. Review.</citation>
    <PMID>8821415</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2018</study_first_submitted>
  <study_first_submitted_qc>January 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>January 28, 2018</last_update_submitted>
  <last_update_submitted_qc>January 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

